| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1043-2760(01)00438-6 |
| P698 | PubMed publication ID | 11504668 |
| P2093 | author name string | Göttlicher M | |
| Heinzel T | |||
| Krämer OH | |||
| P2860 | cites work | Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation | Q22003769 |
| Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4 | Q24313176 | ||
| ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors | Q24522848 | ||
| ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex | Q24653699 | ||
| Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors | Q27619648 | ||
| Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase | Q27860668 | ||
| The language of covalent histone modifications | Q27860931 | ||
| Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells | Q28142463 | ||
| SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions? | Q28236020 | ||
| What's up and down with histone deacetylation and transcription? | Q28238059 | ||
| Role of the histone deacetylase complex in acute promyelocytic leukaemia | Q28263534 | ||
| Rb interacts with histone deacetylase to repress transcription | Q28263985 | ||
| A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p | Q28276243 | ||
| Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 | Q28377610 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia | Q29616211 | ||
| Multiple regions of ETO cooperate in transcriptional repression | Q31813206 | ||
| Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells | Q31858549 | ||
| Induction of MAGE-3 expression in lung and esophageal cancer cells | Q32054392 | ||
| Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation | Q32085914 | ||
| Histone acetylases and deacetylases in cell proliferation | Q33540069 | ||
| Histone acetylation and cancer | Q33632377 | ||
| Histone deacetylases, transcriptional control, and cancer | Q33926323 | ||
| Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes | Q33941116 | ||
| Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies | Q34067921 | ||
| Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors | Q34091001 | ||
| The human histone deacetylase family | Q34119283 | ||
| FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. | Q34472558 | ||
| Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells | Q34480485 | ||
| The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. | Q34480893 | ||
| Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin | Q34584029 | ||
| A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors | Q35134137 | ||
| A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. | Q35976663 | ||
| Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase | Q35999927 | ||
| Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells. | Q36135022 | ||
| p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells | Q36489810 | ||
| Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. | Q39576827 | ||
| Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function | Q40547910 | ||
| Butyrate as a differentiating agent: pharmacokinetics, analogues and current status | Q40751544 | ||
| Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells | Q40840344 | ||
| Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor | Q40898485 | ||
| Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. | Q40933096 | ||
| Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells | Q41046408 | ||
| Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites | Q41066638 | ||
| bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis | Q41090305 | ||
| Altered retinoic acid receptors. | Q41108310 | ||
| Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate | Q41863296 | ||
| Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. | Q43551866 | ||
| Covalent modifications of histones: expression from chromatin templates | Q48018634 | ||
| IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cells. | Q52277711 | ||
| Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. | Q53408223 | ||
| Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. | Q53453650 | ||
| Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. | Q54117344 | ||
| Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. | Q54147247 | ||
| Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. | Q54505728 | ||
| Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase | Q57228797 | ||
| Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines | Q57228840 | ||
| Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice | Q71380082 | ||
| Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors | Q73306842 | ||
| Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells | Q73622276 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 294-300 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Trends in Endocrinology and Metabolism | Q15265727 |
| P1476 | title | Histone deacetylase as a therapeutic target | |
| P478 | volume | 12 |
| Q35799771 | A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. |
| Q44643741 | A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis |
| Q38315771 | Acetylation of Stat1 modulates NF-kappaB activity |
| Q39677863 | Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation |
| Q41857738 | Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer |
| Q48818809 | Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus |
| Q40246576 | Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition |
| Q36601836 | Baculovirus vectors for gene therapy |
| Q34563296 | Biotechnologies and therapeutics: chromatin as a target. |
| Q40717620 | Cell-line specific chromatin acetylation at the Sox10-Pax3 enhancer site modulates the RET proto-oncogene expression. |
| Q37405334 | Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis |
| Q40087324 | Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo |
| Q42324101 | Comparison of Anticancer Effects of Carbamazepine and Valproic Acid |
| Q35595888 | Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells |
| Q36972324 | Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock |
| Q24562818 | Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor |
| Q34350588 | Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription |
| Q40251788 | Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. |
| Q33688771 | DNA methylation: a mechanism for embedding early life experiences in the genome |
| Q33713396 | Development of a hybrid baculoviral vector for sustained transgene expression |
| Q46316392 | Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest |
| Q36083466 | ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. |
| Q23917136 | Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells |
| Q35064126 | Emerging cancer-targeted therapies |
| Q30670644 | Enhanced angiogenesis in ischemic skeletal muscle after transplantation of cell sheets from baculovirus-transduced adipose-derived stromal cells expressing VEGF165 |
| Q93082245 | Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy |
| Q60907794 | Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53 |
| Q39676602 | Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin |
| Q33848607 | Epigenetics, behaviour, and health |
| Q36387871 | Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation |
| Q34088777 | Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression |
| Q50660681 | HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation |
| Q34495315 | HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter |
| Q34749665 | HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure |
| Q34666783 | Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells |
| Q37281996 | Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition. |
| Q36138397 | Histone Deacetylation of RB-Responsive Promoters: Requisite for Specific Gene Repression but Dispensable for Cell Cycle Inhibition |
| Q91450885 | Histone deacetylase 4 (HDAC4): a new player in anorexia nervosa? |
| Q34503302 | Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells |
| Q35893218 | Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology |
| Q40088575 | Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells |
| Q40102582 | Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis |
| Q40511487 | Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells |
| Q40450785 | Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. |
| Q40543132 | Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells |
| Q35011880 | Histone deacetylase inhibitors: from target to clinical trials |
| Q24535587 | Histone deacetylases (HDACs): characterization of the classical HDAC family |
| Q37389553 | Histone deacetylases: salesmen and customers in the post-translational modification market. |
| Q34743301 | Histone-deacetylase inhibitors: novel drugs for the treatment of cancer |
| Q40386669 | Identification of MMP-15 as an anti-apoptotic factor in cancer cells |
| Q44897188 | Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis |
| Q81308372 | Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 |
| Q46346613 | Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy |
| Q38821833 | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| Q48151381 | LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation |
| Q34635234 | Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock |
| Q34774151 | New drugs in acute myeloid leukemia |
| Q35739676 | Nonhistone protein acetylation as cancer therapy targets |
| Q34448240 | Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation |
| Q33364474 | Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors |
| Q44386104 | Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number |
| Q57240427 | Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling |
| Q35563857 | Recent progress in the development of assays suited for histone deacetylase inhibitor screening |
| Q34694229 | Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications |
| Q28204822 | Regulation of lifespan by histone deacetylase |
| Q39169468 | Selection of an improved HDAC8 inhibitor through structure-based drug design |
| Q34575681 | Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4 |
| Q38835024 | Streptanoate, a new anticancer butanoate from Streptomyces sp. DC3. |
| Q36413292 | Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition |
| Q33634679 | Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. |
| Q39385998 | TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells |
| Q38066990 | Targeting histone deacetylase in thyroid cancer. |
| Q24652979 | The Wnt-dependent signaling pathways as target in oncology drug discovery |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q36901377 | The dynamic epigenome and its implications in toxicology |
| Q43139216 | The effects of DNA methyltransferase inhibitors and histone deacetylase inhibitors on digit regeneration in mice |
| Q39369222 | The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression |
| Q35160462 | The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 |
| Q37346960 | The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity |
| Q37800949 | The targets of curcumin. |
| Q34888585 | The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. |
| Q36429409 | Therapeutic implications of DNA methylation |
| Q33862991 | Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
| Q44555704 | Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes |
| Q44207181 | Trifluoromethyl ketones as inhibitors of histone deacetylase |
| Q28181623 | VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression |
| Q28366303 | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells |
| Q39013397 | Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4/URGCP and CCND1 gene expression |
| Q39570650 | Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. |
| Q36623251 | Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases |
| Q92083193 | p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death |
| Q28213515 | p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y |
Search more.